Immuno Oncology

This is an example
Extrapulmonary Neuroendocrine Carcinoma: Clinical Overview and Advances in DLL3 Targeted Therapy
Late Breaking Abstract – 2026 ASCO GU Symposium: Advancing Adjuvant Therapy in Clear Cell Renal Cell Carcinoma
Adjuvant Nivolumab for Resected Melanoma: 9 Year Outcomes
FDA Approves KEYTRUDA® with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian tube, or Primary Peritoneal Carcinoma
Late Breaking Abstract – ASH 2025: Teclistamab Plus Daratumumab Redefines Outcomes in Early Relapsed Multiple Myeloma
Late Breaking Abstract – ESMO 2025: Advancing First-Line Therapy in High-Risk NMIBC: Final Results from the Phase III POTOMAC Trial
Durvalumab + FLOT Establishes New Benchmark in Curative-Intent Therapy for Gastric and GEJ Cancers
FDA Approves LIBTAYO® for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma
FDA Approves ZEPZELCA® Plus TECENTRIQ® for First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer
CAN-2409 in Advanced NSCLC: Turning Tumors into Vaccines
Tarlatamab Sets New Standard in Recurrent Small Cell Lung Cancer: Results from DeLLphi-304
Adjuvant Atezolizumab in Resected NSCLC: Five-Year Outcomes from IMpower010
Neoadjuvant PD-1 Blockade Promotes Organ Preservation in Early Stage Mismatch Repair–Deficient Solid Tumors
OPDIVO Qvantig^TM (nivolumab + hyaluronidase-nvhy) is delivered via subcutaneous injection, streamlining administration for eligible patients^{1^*}
Three-Year Overall Survival with OPDUALAG® in Advanced Melanoma
FDA Approves Perioperative KEYTRUDA® for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Late Breaking Abstract – ASCO 2025: Tarlatamab Sets New Standard in Recurrent Small Cell Lung Cancer: Results from DeLLphi-304
Late Breaking Abstract – ASCO 2025: Durvalumab Plus FLOT Demonstrates Significant EFS Improvement in Resectable Gastric and GE Junction Cancers: Interim Results from the Phase 3 MATTERHORN Trial
Late Breaking Abstract – ASCO 2025: Adjuvant Immunotherapy Improves Outcomes in Stage III dMMR Colon Cancer: Results from the ATOMIC Trial

Top Ad

This is an example

Extrapulmonary Neuroendocrine Carcinoma: Clinical Overview and Advances in DLL3 Targeted Therapy

Late Breaking Abstract – 2026 ASCO GU Symposium: Advancing Adjuvant Therapy in Clear Cell Renal Cell Carcinoma

Adjuvant Nivolumab for Resected Melanoma: 9 Year Outcomes

FDA Approves KEYTRUDA® with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian tube, or Primary Peritoneal Carcinoma

Late Breaking Abstract – ASH 2025: Teclistamab Plus Daratumumab Redefines Outcomes in Early Relapsed Multiple Myeloma

Late Breaking Abstract – ESMO 2025: Advancing First-Line Therapy in High-Risk NMIBC: Final Results from the Phase III POTOMAC Trial

Durvalumab + FLOT Establishes New Benchmark in Curative-Intent Therapy for Gastric and GEJ Cancers

FDA Approves LIBTAYO® for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma

FDA Approves ZEPZELCA® Plus TECENTRIQ® for First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer

CAN-2409 in Advanced NSCLC: Turning Tumors into Vaccines

Tarlatamab Sets New Standard in Recurrent Small Cell Lung Cancer: Results from DeLLphi-304

Adjuvant Atezolizumab in Resected NSCLC: Five-Year Outcomes from IMpower010

Neoadjuvant PD-1 Blockade Promotes Organ Preservation in Early Stage Mismatch Repair–Deficient Solid Tumors

OPDIVO Qvantig^TM (nivolumab + hyaluronidase-nvhy) is delivered via subcutaneous injection, streamlining administration for eligible patients^{1^*}

Three-Year Overall Survival with OPDUALAG® in Advanced Melanoma

FDA Approves Perioperative KEYTRUDA® for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Late Breaking Abstract – ASCO 2025: Tarlatamab Sets New Standard in Recurrent Small Cell Lung Cancer: Results from DeLLphi-304

Late Breaking Abstract – ASCO 2025: Durvalumab Plus FLOT Demonstrates Significant EFS Improvement in Resectable Gastric and GE Junction Cancers: Interim Results from the Phase 3 MATTERHORN Trial

Late Breaking Abstract – ASCO 2025: Adjuvant Immunotherapy Improves Outcomes in Stage III dMMR Colon Cancer: Results from the ATOMIC Trial

Bottom Ad

Subscribe